Former US president Jimmy Carter Says His Brain Cancer Has Disappeared

LAS VEGAS, NV / ACCESSWIRE / January 20, 2015 / Carter was given pembrolizumab, one of the most exciting new drugs in cancer treatment today. Pembrolizumab, is one of the first immunotherapy drugs. Instead of killing cancer cells, these drugs boost the immune system to do the job.

Propanc Health Group Corp. (PPCH) is developing an immunotherapy of sorts for pancreatic cancer. Their drug targets cancer cell death whilst also boosting the immune response. For more information visit www.propanc.com.

There are 338,000 new cases of pancreatic cancer are diagnosed each year, making the global market for treating this cancer at roughly $9 billion.

PPCH has just released very compelling news of shrinking pancreatic cancer tumors in mice by 84% in only 26 days. At this point the company is financed to get to the next step which is their Initial New Drug application.

Investors have been loading up at these levels anticipating potentially large price appreciation as the next events come to fruition.

Here’s a few other interesting biotechs:

Arena Pharmaceuticals, Inc. (ARNA), a firm in the Medical-Biomedical/Generic space, could be a great candidate to beat earnings estimates. This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, ARNA has beaten estimates by at least 20% in both cases, suggesting it has a nice short-term history of crushing expectations. Arena embraces the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena's focus is discovering, developing and commercializing drugs to address unmet medical needs, and BELVIQ(R) (lorcaserin HCl) is Arena's first internally discovered drug approved for marketing. Arena has US operations located in San Diego, California, and operations outside of the United States, including its commercial manufacturing facility, located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.

Inovio Pharmaceuticals, Inc. (INO), a medical - biomed/gene stock, has seen loss estimates narrow over the past month for the current fiscal year by about 35.5%. But that is not yet reflected in its price, as the stock has actually lost 3.3% over the same time frame. You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 37.9%, which should ultimately translate into price appreciation.

Keryx Biopharmaceuticals (KERX), with offices in New York and Boston, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia(TM) (ferric citrate) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona(R) by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric(R) (ferric citrate coordination complex) for the control of hyperphosphatemia in adults with non-dialysis and dialysis-dependent chronic kidney disease.

PPCH’s proenzyme immunotherapy could be one of many treatments that help lead to significantly reducing the mortality rates associated with cancer. Former President Carter is just one of many people experiencing the benefits of immunotherapy. Companies like PPCH and their belief that “their treatment will provide a competitive advantage over other treatments available,” should prove to be a big winner their shareholders. Make sure to take a close look at this high potential biotech.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC., which owns Microcapspeculators.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC., which owns Microcapspeculators.com, may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $10,000 cash by A non-affiliate third party of ENDV.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communication, LLC

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.